Literature DB >> 12181311

Definition of an inhibitory juxtamembrane WW-like domain in the platelet-derived growth factor beta receptor.

Pablo M Irusta1, Yue Luo, Omar Bakht, Char-Chang Lai, Steven O Smith, Daniel DiMaio.   

Abstract

A variety of tumors contain activating mutations in the cytoplasmic juxtamembrane domain of the type III family of receptor-tyrosine kinases, and some constructed mutations in this domain induce ligand-independent receptor activation. To explore the role of this domain in regulation of receptor activity, we subjected the juxtamembrane domain of the murine platelet-derived growth factor (PDGF) beta receptor to alanine-scanning mutagenesis. The mutant receptors were expressed in Ba/F3 cells and tested for constitutive tyrosine phosphorylation, association with phosphatidylinositol 3'-kinase, and their ability to induce cell survival and proliferation in the absence of interleukin-3. The mutant receptors accumulated to similar levels and appeared to undergo a normal PDGF-induced increase in tyrosine phosphorylation. Alanine substitutions at numerous positions located throughout the juxtamembrane domain caused constitutive receptor activation, as did an alanine insertion in the membrane-proximal segment of the juxtamembrane domain and a six-amino acid deletion in the center of the domain. It is possible to model the PDGF receptor juxtamembrane domain as a short alpha-helix followed by a three-stranded beta-sheet very similar to the known structures of WW domains. Strikingly, the activating mutations clustered in the central portions of the first and second beta strands and along one face of the beta-sheet, whereas the loops connecting the strands were largely devoid of mutationally sensitive positions. These findings provide strong support for the model that the activating mutations in the juxtamembrane region stimulate receptor activity by disrupting an inhibitory WW-like domain.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12181311     DOI: 10.1074/jbc.M204890200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent.

Authors:  Elizabeth H Stover; Jing Chen; Cedric Folens; Benjamin H Lee; Nicole Mentens; Peter Marynen; Ifor R Williams; D Gary Gilliland; Jan Cools
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-11       Impact factor: 11.205

2.  Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis.

Authors:  Jean-Baptiste Demoulin; Carmen P Montano-Almendras
Journal:  Am J Blood Res       Date:  2012-01-01

3.  Somatic PDGFRB Activating Variants in Fusiform Cerebral Aneurysms.

Authors:  Yigit Karasozen; Joshua W Osbun; Carolina Angelica Parada; Tina Busald; Philip Tatman; Luis F Gonzalez-Cuyar; Christopher J Hale; Diana Alcantara; Mark O'Driscoll; William B Dobyns; Mitzi Murray; Louis J Kim; Peter Byers; Michael O Dorschner; Manuel Ferreira
Journal:  Am J Hum Genet       Date:  2019-04-25       Impact factor: 11.025

Review 4.  Structural and functional properties of platelet-derived growth factor and stem cell factor receptors.

Authors:  Carl-Henrik Heldin; Johan Lennartsson
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-08-01       Impact factor: 10.005

5.  Critical role of the platelet-derived growth factor receptor (PDGFR) beta transmembrane domain in the TEL-PDGFRbeta cytosolic oncoprotein.

Authors:  Federica Toffalini; Carina Hellberg; Jean-Baptiste Demoulin
Journal:  J Biol Chem       Date:  2010-02-17       Impact factor: 5.157

6.  Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas.

Authors:  Barbara S Paugh; Xiaoyan Zhu; Chunxu Qu; Raelene Endersby; Alexander K Diaz; Junyuan Zhang; Dorine A Bax; Diana Carvalho; Rui M Reis; Arzu Onar-Thomas; Alberto Broniscer; Cynthia Wetmore; Jinghui Zhang; Chris Jones; David W Ellison; Suzanne J Baker
Journal:  Cancer Res       Date:  2013-08-22       Impact factor: 12.701

7.  Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis.

Authors:  Philipp Erben; Darko Gosenca; Martin C Müller; Jelena Reinhard; Joannah Score; Francesco Del Valle; Christoph Walz; Jürgen Mix; Georgia Metzgeroth; Thomas Ernst; Claudia Haferlach; Nicholas C P Cross; Andreas Hochhaus; Andreas Reiter
Journal:  Haematologica       Date:  2010-01-27       Impact factor: 9.941

8.  Patterns of somatic mutation in human cancer genomes.

Authors:  Christopher Greenman; Philip Stephens; Raffaella Smith; Gillian L Dalgliesh; Christopher Hunter; Graham Bignell; Helen Davies; Jon Teague; Adam Butler; Claire Stevens; Sarah Edkins; Sarah O'Meara; Imre Vastrik; Esther E Schmidt; Tim Avis; Syd Barthorpe; Gurpreet Bhamra; Gemma Buck; Bhudipa Choudhury; Jody Clements; Jennifer Cole; Ed Dicks; Simon Forbes; Kris Gray; Kelly Halliday; Rachel Harrison; Katy Hills; Jon Hinton; Andy Jenkinson; David Jones; Andy Menzies; Tatiana Mironenko; Janet Perry; Keiran Raine; Dave Richardson; Rebecca Shepherd; Alexandra Small; Calli Tofts; Jennifer Varian; Tony Webb; Sofie West; Sara Widaa; Andy Yates; Daniel P Cahill; David N Louis; Peter Goldstraw; Andrew G Nicholson; Francis Brasseur; Leendert Looijenga; Barbara L Weber; Yoke-Eng Chiew; Anna DeFazio; Mel F Greaves; Anthony R Green; Peter Campbell; Ewan Birney; Douglas F Easton; Georgia Chenevix-Trench; Min-Han Tan; Sok Kean Khoo; Bin Tean Teh; Siu Tsan Yuen; Suet Yi Leung; Richard Wooster; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2007-03-08       Impact factor: 49.962

Review 9.  Targeting the PDGF signaling pathway in tumor treatment.

Authors:  Carl-Henrik Heldin
Journal:  Cell Commun Signal       Date:  2013-12-20       Impact factor: 5.712

10.  The structures of the kinase domain and UBA domain of MPK38 suggest the activation mechanism for kinase activity.

Authors:  Yong-Soon Cho; Jiho Yoo; Soomin Park; Hyun-Soo Cho
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2014-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.